Cargando…
Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
PURPOSE: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. DESIGN AND METHODS: A Markov model was develope...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309959/ https://www.ncbi.nlm.nih.gov/pubmed/32685568 http://dx.doi.org/10.36469/9777 |
_version_ | 1783549275237515264 |
---|---|
author | Tirado Mercier, Eva Callejo Velasco, Daniel Rubio Cabezas, Marta Moretones Agut, Cristina Granell Villalón, Meritxell |
author_facet | Tirado Mercier, Eva Callejo Velasco, Daniel Rubio Cabezas, Marta Moretones Agut, Cristina Granell Villalón, Meritxell |
author_sort | Tirado Mercier, Eva |
collection | PubMed |
description | PURPOSE: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. DESIGN AND METHODS: A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. RESULTS: Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. CONCLUSIONS: Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty. |
format | Online Article Text |
id | pubmed-7309959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Columbia Data Analytics, LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-73099592020-07-16 Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain Tirado Mercier, Eva Callejo Velasco, Daniel Rubio Cabezas, Marta Moretones Agut, Cristina Granell Villalón, Meritxell J Health Econ Outcomes Res Oncology PURPOSE: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. DESIGN AND METHODS: A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. RESULTS: Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. CONCLUSIONS: Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources’ utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty. Columbia Data Analytics, LLC 2018-01-29 /pmc/articles/PMC7309959/ /pubmed/32685568 http://dx.doi.org/10.36469/9777 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CCBY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 and legal code at http://creativecommons.org/licenses/by/4.0/legalcode for more information. |
spellingShingle | Oncology Tirado Mercier, Eva Callejo Velasco, Daniel Rubio Cabezas, Marta Moretones Agut, Cristina Granell Villalón, Meritxell Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title_full | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title_fullStr | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title_full_unstemmed | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title_short | Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain |
title_sort | cost-effectiveness analysis of radium-223 dichloride in metastatic castration-resistant prostate cancer patients without previous chemotherapy treatment in spain |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309959/ https://www.ncbi.nlm.nih.gov/pubmed/32685568 http://dx.doi.org/10.36469/9777 |
work_keys_str_mv | AT tiradomerciereva costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT callejovelascodaniel costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT rubiocabezasmarta costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT moretonesagutcristina costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain AT granellvillalonmeritxell costeffectivenessanalysisofradium223dichlorideinmetastaticcastrationresistantprostatecancerpatientswithoutpreviouschemotherapytreatmentinspain |